2018-2023 Global Pulmonary Hypertension Drug Consumption Market Report

October 2018 | 133 pages | ID: 2A2DDDD4720EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Pulmonary Hypertension Drug market for 2018-2023.

Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.
Over the next five years, LPI(LP Information) projects that Pulmonary Hypertension Drug will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Hypertension Drug market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Prostacyclin and Prostacyclin Analogs
• Endothelin Receptor Antagonists
• Phosphodiesterase-5 Inhibitors
• Soluble Guanylate Cyclase Stimulators

Segmentation by application:

• Early-stage Drug Candidates (Phase I & Phase II)
• Late-stage Drug Candidates (Phase III & Registration Phase)

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• AstraZeneca plc
• F. Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd.
• Vectura Group plc
• Pfizer Inc.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Pulmonary Hypertension Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Pulmonary Hypertension Drug market by identifying its various subsegments.
• Focuses on the key global Pulmonary Hypertension Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Pulmonary Hypertension Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Pulmonary Hypertension Drug submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Pulmonary Hypertension Drug Consumption 2013-2023
  2.1.2 Pulmonary Hypertension Drug Consumption CAGR by Region
2.2 Pulmonary Hypertension Drug Segment by Type
  2.2.1 Prostacyclin and Prostacyclin Analogs
  2.2.2 Endothelin Receptor Antagonists
  2.2.3 Phosphodiesterase-5 Inhibitors
  2.2.4 Soluble Guanylate Cyclase Stimulators
2.3 Pulmonary Hypertension Drug Consumption by Type
  2.3.1 Global Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
  2.3.2 Global Pulmonary Hypertension Drug Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Pulmonary Hypertension Drug Sale Price by Type (2013-2018)
2.4 Pulmonary Hypertension Drug Segment by Application
  2.4.1 Early-stage Drug Candidates (Phase I & Phase II)
  2.4.2 Late-stage Drug Candidates (Phase III & Registration Phase)
2.5 Pulmonary Hypertension Drug Consumption by Application
  2.5.1 Global Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
  2.5.2 Global Pulmonary Hypertension Drug Value and Market Share by Application (2013-2018)
  2.5.3 Global Pulmonary Hypertension Drug Sale Price by Application (2013-2018)

3 GLOBAL PULMONARY HYPERTENSION DRUG BY PLAYERS

3.1 Global Pulmonary Hypertension Drug Sales Market Share by Players
  3.1.1 Global Pulmonary Hypertension Drug Sales by Players (2016-2018)
  3.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Players (2016-2018)
3.2 Global Pulmonary Hypertension Drug Revenue Market Share by Players
  3.2.1 Global Pulmonary Hypertension Drug Revenue by Players (2016-2018)
  3.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Players (2016-2018)
3.3 Global Pulmonary Hypertension Drug Sale Price by Players
3.4 Global Pulmonary Hypertension Drug Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Pulmonary Hypertension Drug Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Pulmonary Hypertension Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 PULMONARY HYPERTENSION DRUG BY REGIONS

4.1 Pulmonary Hypertension Drug by Regions
  4.1.1 Global Pulmonary Hypertension Drug Consumption by Regions
  4.1.2 Global Pulmonary Hypertension Drug Value by Regions
4.2 Americas Pulmonary Hypertension Drug Consumption Growth
4.3 APAC Pulmonary Hypertension Drug Consumption Growth
4.4 Europe Pulmonary Hypertension Drug Consumption Growth
4.5 Middle East & Africa Pulmonary Hypertension Drug Consumption Growth

5 AMERICAS

5.1 Americas Pulmonary Hypertension Drug Consumption by Countries
  5.1.1 Americas Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
  5.1.2 Americas Pulmonary Hypertension Drug Value by Countries (2013-2018)
5.2 Americas Pulmonary Hypertension Drug Consumption by Type
5.3 Americas Pulmonary Hypertension Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Pulmonary Hypertension Drug Consumption by Countries
  6.1.1 APAC Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
  6.1.2 APAC Pulmonary Hypertension Drug Value by Countries (2013-2018)
6.2 APAC Pulmonary Hypertension Drug Consumption by Type
6.3 APAC Pulmonary Hypertension Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Pulmonary Hypertension Drug by Countries
  7.1.1 Europe Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
  7.1.2 Europe Pulmonary Hypertension Drug Value by Countries (2013-2018)
7.2 Europe Pulmonary Hypertension Drug Consumption by Type
7.3 Europe Pulmonary Hypertension Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Pulmonary Hypertension Drug by Countries
  8.1.1 Middle East & Africa Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Pulmonary Hypertension Drug Value by Countries (2013-2018)
8.2 Middle East & Africa Pulmonary Hypertension Drug Consumption by Type
8.3 Middle East & Africa Pulmonary Hypertension Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Pulmonary Hypertension Drug Distributors
10.3 Pulmonary Hypertension Drug Customer

11 GLOBAL PULMONARY HYPERTENSION DRUG MARKET FORECAST

11.1 Global Pulmonary Hypertension Drug Consumption Forecast (2018-2023)
11.2 Global Pulmonary Hypertension Drug Forecast by Regions
  11.2.1 Global Pulmonary Hypertension Drug Forecast by Regions (2018-2023)
  11.2.2 Global Pulmonary Hypertension Drug Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Pulmonary Hypertension Drug Forecast by Type
11.8 Global Pulmonary Hypertension Drug Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 GlaxoSmithKline plc
  12.1.1 Company Details
  12.1.2 Pulmonary Hypertension Drug Product Offered
  12.1.3 GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 GlaxoSmithKline plc News
12.2 Novartis AG
  12.2.1 Company Details
  12.2.2 Pulmonary Hypertension Drug Product Offered
  12.2.3 Novartis AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Novartis AG News
12.3 Merck & Co., Inc.
  12.3.1 Company Details
  12.3.2 Pulmonary Hypertension Drug Product Offered
  12.3.3 Merck & Co., Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 Merck & Co., Inc. News
12.4 Abbott Laboratories
  12.4.1 Company Details
  12.4.2 Pulmonary Hypertension Drug Product Offered
  12.4.3 Abbott Laboratories Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 Abbott Laboratories News
12.5 Boehringer Ingelheim GmbH
  12.5.1 Company Details
  12.5.2 Pulmonary Hypertension Drug Product Offered
  12.5.3 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Boehringer Ingelheim GmbH News
12.6 AstraZeneca plc
  12.6.1 Company Details
  12.6.2 Pulmonary Hypertension Drug Product Offered
  12.6.3 AstraZeneca plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 AstraZeneca plc News
12.7 F. Hoffmann-La Roche AG
  12.7.1 Company Details
  12.7.2 Pulmonary Hypertension Drug Product Offered
  12.7.3 F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 F. Hoffmann-La Roche AG News
12.8 Teva Pharmaceutical Industries Ltd.
  12.8.1 Company Details
  12.8.2 Pulmonary Hypertension Drug Product Offered
  12.8.3 Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 Teva Pharmaceutical Industries Ltd. News
12.9 Vectura Group plc
  12.9.1 Company Details
  12.9.2 Pulmonary Hypertension Drug Product Offered
  12.9.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Vectura Group plc News
12.10 Pfizer Inc.
  12.10.1 Company Details
  12.10.2 Pulmonary Hypertension Drug Product Offered
  12.10.3 Pfizer Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 Pfizer Inc. News

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Pulmonary Hypertension Drug
Table Product Specifications of Pulmonary Hypertension Drug
Figure Pulmonary Hypertension Drug Report Years Considered
Figure Market Research Methodology
Figure Global Pulmonary Hypertension Drug Consumption Growth Rate 2013-2023 (MT)
Figure Global Pulmonary Hypertension Drug Value Growth Rate 2013-2023 ($ Millions)
Table Pulmonary Hypertension Drug Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Prostacyclin and Prostacyclin Analogs
Table Major Players of Prostacyclin and Prostacyclin Analogs
Figure Product Picture of Endothelin Receptor Antagonists
Table Major Players of Endothelin Receptor Antagonists
Figure Product Picture of Phosphodiesterase-5 Inhibitors
Table Major Players of Phosphodiesterase-5 Inhibitors
Figure Product Picture of Soluble Guanylate Cyclase Stimulators
Table Major Players of Soluble Guanylate Cyclase Stimulators
Table Global Consumption Sales by Type (2013-2018)
Table Global Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Global Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Table Global Pulmonary Hypertension Drug Revenue by Type (2013-2018) ($ million)
Table Global Pulmonary Hypertension Drug Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Pulmonary Hypertension Drug Value Market Share by Type (2013-2018)
Table Global Pulmonary Hypertension Drug Sale Price by Type (2013-2018)
Figure Pulmonary Hypertension Drug Consumed in Early-stage Drug Candidates (Phase I & Phase II)
Figure Global Pulmonary Hypertension Drug Market: Early-stage Drug Candidates (Phase I & Phase II) (2013-2018) (MT)
Figure Global Pulmonary Hypertension Drug Market: Early-stage Drug Candidates (Phase I & Phase II) (2013-2018) ($ Millions)
Figure Global Early-stage Drug Candidates (Phase I & Phase II) YoY Growth ($ Millions)
Figure Pulmonary Hypertension Drug Consumed in Late-stage Drug Candidates (Phase III & Registration Phase)
Figure Global Pulmonary Hypertension Drug Market: Late-stage Drug Candidates (Phase III & Registration Phase) (2013-2018) (MT)
Figure Global Pulmonary Hypertension Drug Market: Late-stage Drug Candidates (Phase III & Registration Phase) (2013-2018) ($ Millions)
Figure Global Late-stage Drug Candidates (Phase III & Registration Phase) YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Global Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Value by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Value Market Share by Application (2013-2018)
Figure Global Pulmonary Hypertension Drug Value Market Share by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Sale Price by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Sales by Players (2016-2018) (MT)
Table Global Pulmonary Hypertension Drug Sales Market Share by Players (2016-2018)
Figure Global Pulmonary Hypertension Drug Sales Market Share by Players in 2016
Figure Global Pulmonary Hypertension Drug Sales Market Share by Players in 2017
Table Global Pulmonary Hypertension Drug Revenue by Players (2016-2018) ($ Millions)
Table Global Pulmonary Hypertension Drug Revenue Market Share by Players (2016-2018)
Figure Global Pulmonary Hypertension Drug Revenue Market Share by Players in 2016
Figure Global Pulmonary Hypertension Drug Revenue Market Share by Players in 2017
Table Global Pulmonary Hypertension Drug Sale Price by Players (2016-2018)
Figure Global Pulmonary Hypertension Drug Sale Price by Players in 2017
Table Global Pulmonary Hypertension Drug Manufacturing Base Distribution and Sales Area by Players
Table Players Pulmonary Hypertension Drug Products Offered
Table Pulmonary Hypertension Drug Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Pulmonary Hypertension Drug Consumption by Regions 2013-2018 (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Share by Regions 2013-2018
Figure Global Pulmonary Hypertension Drug Consumption Market Share by Regions 2013-2018
Table Global Pulmonary Hypertension Drug Value by Regions 2013-2018 ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share by Regions 2013-2018
Figure Global Pulmonary Hypertension Drug Value Market Share by Regions 2013-2018
Figure Americas Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure Americas Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Figure APAC Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure APAC Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Figure Europe Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure Europe Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure Middle East & Africa Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Table Americas Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table Americas Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure Americas Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table Americas Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table Americas Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure Americas Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table Americas Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table Americas Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Americas Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table Americas Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table Americas Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Americas Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure United States Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure United States Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Canada Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Canada Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Mexico Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Mexico Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table APAC Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table APAC Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure APAC Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table APAC Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table APAC Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure APAC Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table APAC Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table APAC Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure APAC Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table APAC Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table APAC Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure APAC Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure China Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure China Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Japan Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Japan Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Korea Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Korea Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Southeast Asia Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure India Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure India Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Australia Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Australia Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table Europe Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table Europe Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure Europe Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table Europe Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table Europe Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure Europe Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table Europe Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table Europe Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Europe Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table Europe Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table Europe Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Europe Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure Germany Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Germany Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure France Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure France Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure UK Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure UK Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Italy Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Italy Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Russia Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Russia Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Spain Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Spain Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table Middle East & Africa Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table Middle East & Africa Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table Middle East & Africa Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure Egypt Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Egypt Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure South Africa Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure South Africa Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Israel Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Israel Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Turkey Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Turkey Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure GCC Countries Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table Pulmonary Hypertension Drug Distributors List
Table Pulmonary Hypertension Drug Customer List
Figure Global Pulmonary Hypertension Drug Consumption Growth Rate Forecast (2018-2023) (MT)
Figure Global Pulmonary Hypertension Drug Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Consumption Forecast by Countries (2018-2023) (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Forecast by Regions
Table Global Pulmonary Hypertension Drug Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share Forecast by Regions
Figure Americas Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Americas Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure APAC Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure APAC Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Europe Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Europe Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Middle East & Africa Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure United States Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure United States Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Canada Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Canada Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Mexico Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Mexico Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Brazil Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Brazil Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure China Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure China Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Japan Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Japan Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Korea Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Korea Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Southeast Asia Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Southeast Asia Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure India Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure India Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Australia Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Australia Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Germany Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Germany Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure France Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure France Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure UK Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure UK Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Italy Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Italy Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Russia Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Russia Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Spain Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Spain Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Egypt Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Egypt Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure South Africa Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure South Africa Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Israel Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Israel Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Turkey Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Turkey Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure GCC Countries Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure GCC Countries Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Table Global Pulmonary Hypertension Drug Consumption Forecast by Type (2018-2023) (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Share Forecast by Type (2018-2023)
Table Global Pulmonary Hypertension Drug Value Forecast by Type (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share Forecast by Type (2018-2023)
Table Global Pulmonary Hypertension Drug Consumption Forecast by Application (2018-2023) (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Share Forecast by Application (2018-2023)
Table Global Pulmonary Hypertension Drug Value Forecast by Application (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share Forecast by Application (2018-2023)
Table GlaxoSmithKline plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure GlaxoSmithKline plc Pulmonary Hypertension Drug Market Share (2016-2018)
Table Novartis AG Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Novartis AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Novartis AG Pulmonary Hypertension Drug Market Share (2016-2018)
Table Merck & Co., Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Merck & Co., Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Merck & Co., Inc. Pulmonary Hypertension Drug Market Share (2016-2018)
Table Abbott Laboratories Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Abbott Laboratories Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Abbott Laboratories Pulmonary Hypertension Drug Market Share (2016-2018)
Table Boehringer Ingelheim GmbH Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Market Share (2016-2018)
Table AstraZeneca plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table AstraZeneca plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure AstraZeneca plc Pulmonary Hypertension Drug Market Share (2016-2018)
Table F. Hoffmann-La Roche AG Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Market Share (2016-2018)
Table Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Market Share (2016-2018)
Table Vectura Group plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Vectura Group plc Pulmonary Hypertension Drug Market Share (2016-2018)
Table Pfizer Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Pfizer Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Pfizer Inc. Pulmonary Hypertension Drug Market Share (2016-2018)